CCM
EW icon

Credo Capital Management’s Edwards Lifesciences EW Stock Holding History

Credo Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-128,688
Closed -$1.44M – 171
2013
Q2 		$1.44M Buy
+128,688
New +$1.52M 1.11% 52

Other funds holding EW

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Credo Capital Management's EW Position: Q3 2013 in Review

Credo Capital Management sold out of Edwards Lifesciences (EW) in Q3 2013, closing a stake of 128,688 shares — an estimated $1.44M sold.

Credo Capital Management first reported a position in EW in Q2 2013 and held it in 1 quarter. The position peaked at $1.44M in Q2 2013. 409 funds tracked by Wall St. Rank hold EW as of Q3 2013.

  • Credo Capital Management reported no remaining Edwards Lifesciences position as of Q3 2013 after selling out during the quarter.
  • Credo Capital Management sold 128,688 Edwards Lifesciences shares in Q3 2013, an estimated $1.44M.
  • Credo Capital Management first reported a position in Edwards Lifesciences in Q2 2013 and held it in 1 quarter.
  • Credo Capital Management's Edwards Lifesciences position peaked at $1.44M in Q2 2013.
  • 409 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2013.

Based on Credo Capital Management's 13F filing for Q3 2013, filed 9 Oct 2013.